Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects
about
Angiopoietin-Tie signalling in the cardiovascular and lymphatic systemsSomatic Activating PIK3CA Mutations Cause Venous MalformationCommon and specific effects of TIE2 mutations causing venous malformationsTie1 controls angiopoietin function in vascular remodeling and inflammation.Leveraging a Sturge-Weber Gene Discovery: An Agenda for Future Research.Phosphoinositide 3-kinase: a new kid on the block in vascular anomalies.Localised intravascular coagulation complicating venous malformations in children: Associations and therapeutic options.Somatic PIK3CA mutations as a driver of sporadic venous malformations.Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activationAngiopoietin receptor Tie2 is required for vein specification and maintenance via regulating COUP-TFIITherapeutic targeting of the angiopoietin-TIE pathway.Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.Embryonic Stem Cell-Like Subpopulations in Venous MalformationFibroadipose vascular anomaly treated with sirolimus: Successful outcome in two patients.Advances in the Medical Management of Vascular Anomalies.Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies.[Rapamycin opens the era of targeted molecular therapy of venous malformations].Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma.Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study
P2860
Q28070234-AB7E6899-41EB-4A25-8CF6-A8A96C0FB045Q28270654-DABC8978-6F06-47BC-9E5E-B8EF5C60A79EQ30670028-5D0998DB-DF04-4746-9CAA-7E997E74B582Q30805233-E64F7007-1F78-4085-8423-EE03A01D0EFDQ33902151-D2D23F8C-0CB1-4CD6-BF58-D11F1F650148Q36117648-A1BB8E36-7911-4EDB-91FC-3C36E4211190Q36272665-138FE01E-C7D4-4564-9B97-A1DB5C55C483Q37130685-0AB96928-59B0-4108-AB7E-1FC959714CD1Q37217491-016B1275-C6E7-45FF-AB6F-F161ED4BDA26Q37568176-7D373E2F-0494-43E0-ABAB-828931D0086FQ39321127-2190FD65-DE40-49F8-A671-926D216C8CF9Q39875938-1263A93F-47A2-4655-B012-3D084176B11CQ42372803-F12AF0CA-D9DF-4D1D-96CD-9EBA57C7E32CQ48292344-88ACD218-BDA2-457E-A2D2-A52985E08797Q49711115-D4D84DC9-CC83-42CA-BB2E-4B72274A2C38Q49711122-233BBF16-FD0E-4359-9214-5F5348307B59Q52860072-A5082D11-FCDD-49A4-8343-E72A4B5922BEQ55262749-033423E4-DFB3-4EBC-98BE-075CB27DA555Q58106291-15AAAB98-5A28-4111-9660-A92E1618D12F
P2860
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects
@ast
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects
@en
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects
@nl
type
label
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects
@ast
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects
@en
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects
@nl
prefLabel
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects
@ast
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects
@en
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects
@nl
P2093
P2860
P50
P356
P1476
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects
@en
P2093
Antonella Mendola
Carlo Brugnara
Catherine Legrand
Jennifer Hammer
Julie Soblet
Kyu-Tae Kang
Laurence M Boon
Lauri Eklund
Marjut Natynki
P2860
P304
P356
10.1172/JCI76004
P407
P577
2015-08-10T00:00:00Z